Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani PL, Ascani S, Perriello VM, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Foà R, Visani G, Zaja F, Falini B. Tiacci E, et al. Among authors: rigacci l. N Engl J Med. 2021 May 13;384(19):1810-1823. doi: 10.1056/NEJMoa2031298. N Engl J Med. 2021. PMID: 33979489 Clinical Trial.
The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases.
Rigacci L, Federico M, Martelli M, Zinzani PL, Cavanna L, Bellesi G, Merli F, Alterini R, Petrucci MT, Tani M, Liberati AM, Vitolo U, Pavone V, Cuneo A, Chisesib T, Brugiatelli M; Intergruppo Italiano Linfomi. Rigacci L, et al. Leuk Lymphoma. 2003 Nov;44(11):1911-7. doi: 10.1080/1042819031000123564. Leuk Lymphoma. 2003. PMID: 14738142
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma.
Rambaldi A, Carlotti E, Oldani E, Della Starza I, Baccarani M, Cortelazzo S, Lauria F, Arcaini L, Morra E, Pulsoni A, Rigacci L, Rupolo M, Zaja F, Zinzani PL, Barbui T, Foa R. Rambaldi A, et al. Among authors: rigacci l. Blood. 2005 May 1;105(9):3428-33. doi: 10.1182/blood-2004-06-2490. Epub 2005 Jan 6. Blood. 2005. PMID: 15637137 Free article.
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.
Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C. Gallamini A, et al. Among authors: rigacci l. Blood. 2007 Oct 1;110(7):2316-23. doi: 10.1182/blood-2007-02-074641. Epub 2007 Jun 20. Blood. 2007. PMID: 17581918 Free article. Clinical Trial.
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, Fabbri A, Zaccaria A, Voso MT, Fattori P, Guardigni L, Ronconi S, Cabras MG, Rigacci L, De Renzo A, Marchi E, Stefoni V, Fina M, Pellegrini C, Musuraca G, Derenzini E, Pileri S, Fanti S, Piccaluga PP, Baccarani M. Zinzani PL, et al. Among authors: rigacci l. Lancet Oncol. 2008 Apr;9(4):352-8. doi: 10.1016/S1470-2045(08)70039-1. Epub 2008 Mar 14. Lancet Oncol. 2008. PMID: 18342572 Clinical Trial.
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior.
Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, Rigacci L, Gherlinzoni F, Cantaffa R, Baraldi A, Gallamini A, Zaccaria A, Pulsoni A, Gobbi M, Tassi M, Raspadori D, Leoncini L, Rinaldi A, Sabattini E, Bertoni F, Pileri SA, Lauria F. Forconi F, et al. Among authors: rigacci l. Blood. 2009 Nov 19;114(21):4696-702. doi: 10.1182/blood-2009-03-212449. Epub 2009 Aug 10. Blood. 2009. PMID: 19667403 Free article. Clinical Trial.
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJ, et al. Among authors: rigacci l. Lancet. 2009 Oct 31;374(9700):1512-20. doi: 10.1016/S0140-6736(09)61416-1. Epub 2009 Sep 18. Lancet. 2009. PMID: 19767089 Free article. Clinical Trial.
Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).
Conconi A, Martinelli G, Lopez-Guillermo A, Zinzani PL, Ferreri AJM, Rigacci L, Devizzi L, Vitolo U, Luminari S, Cavalli F, Zucca E. Conconi A, et al. Among authors: rigacci l. Ann Oncol. 2011 Mar;22(3):689-695. doi: 10.1093/annonc/mdq416. Epub 2010 Sep 1. Ann Oncol. 2011. PMID: 20810546 Free article. Clinical Trial.
Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.
Iannitto E, Morabito F, Mancuso S, Gentile M, Montanini A, Augello A, Bongarzoni V, D'Arco A, Di Renzo N, Fazzi R, Franco G, Marasca R, Mulè A, Musso M, Musto P, Pennese E, Piccin A, Rota-Scalabrini D, Visani G, Rigacci L. Iannitto E, et al. Among authors: rigacci l. Br J Haematol. 2011 May;153(3):351-7. doi: 10.1111/j.1365-2141.2011.08597.x. Epub 2011 Mar 4. Br J Haematol. 2011. PMID: 21371003 Free article.
157 results